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Even in its earliest stages, pancreatic ductal adenocarcinoma (PDAC) remains a highly 
lethal disease, with a five-year survival rate of < 10%. This is especially puzzling, given the 
known presence of neoantigens that should be acted upon by the host adaptive immune 
response. These epitopes are not recognized as “self ” by the thymus, and are thus 
vulnerable to immune surveillance and attack. During the course of pancreatic cancer 
progression, immune surveillance is altered, even though the specific components 
responsible for altering anti-tumor immune responses have not yet been identified. 
Using a genetically engineered mouse model of PDAC that recapitulates human PDAC 
progression and secretes chicken ovalbumin (OVA), a moderately immunogenic 
epitope that models neoantigenicity, we investigated changes in the immune infiltrate in 
response to neoantigen exposure in early-stage pancreatic cancer. This was done using 
immunofluorescent staining and immune cell quantitation via HALO software. B cell 
infiltration was correlated to both tissue transformation and tumor grade to examine 
the relationship between antigen exposure and PDAC pathogenesis. Additionally, the 
induction of inflammatory response was examined by comparing B cell quantitation to 
granulocyte count. Our investigation revealed that infiltration of B220+ B lymphocytes 
increased in early stage tumors expressing OVA and corresponded with disease stage, 
progression, and inflammation, demonstrating an early host adaptive immune response 
against neoantigen in pancreatic lesions. Future studies will explore these parameters in 
later stage disease tissue to observe changes in the immune infiltrate and whether or not 
adaptive immune activation declines over time. These findings may further support why 
advances in immunotherapy have yet to yield results in treating patients with pancreatic 
cancer.
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